ASC To Present at the American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting, Data demonstrates HLA-F immunorepression function similar to other HLA-Ib members, HLA-G or E | ASC

Applied StemCell (ASC) will deliver a presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on how the expression of HLA-G or E in donor cells represses host innate immunity in vitro and in vivo, and its potential application in ASC’s “universal cell” strategy.

Similar to HLA-G and E, HLA-F is in the category of nonclassical antigens (HLA-Ib). However, its function is still ambiguous. We over-expressed HLA-F and HLA-F fusion with B2M (HLA-FB), as well as HLA-G as a positive control in HEK293 cell line using our H11-locus-specific TARGATT™ system and evaluated immune-repression activity using nature killer (NK) cell cytotoxicity assays. We found that, similar to HLA-G, both HLA-F and HLA-FB can repress NK cytotoxicity activity in HEK293 cells. To further investigate HLA-F function in other cell lines, we expressed HLA-FB in human iPSCs (ASC’s proprietary TARGATT™ Master iPSC Line) and confirmed similar immune-repression activity in the stem cells using NK cytotoxicity assays.

Please visit to view the presentation.

Topic: Forced HLA-F Expression Represses Nature Killer Cell Induced Cytotoxicity

Date: Tuesday, May 11, 8:00 AM

Presenter: Kai Wang, Scientist, R&D Cell Group

Authors: Kai Wang, Xiuling Chi, Alfonso Farruggio, Ruby Y. Chen-Tsai, Applied StemCell, Inc., Milpitas, CA

More information can be found at